PMID- 33725113
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220609
IS  - 2058-1742 (Electronic)
IS  - 2058-1742 (Linking)
VI  - 8
IP  - 4
DP  - 2022 Jun 6
TI  - Utilization of sacubitril/valsartan in patients with heart failure with reduced 
      ejection fraction: real-world data from the ARIADNE registry.
PG  - 469-477
LID - 10.1093/ehjqcco/qcab019 [doi]
AB  - AIMS: To compare baseline characteristics of patients with heart failure with 
      reduced ejection fraction (HFrEF) initiated on sacubitril/valsartan compared with 
      patients continued on conventional heart failure (HF)-treatment in a European 
      out-patient setting. METHODS AND RESULTS: Between July 2016 and July 2019, 
      ARIADNE enrolled 8787 outpatients aged >/=18 years with HFrEF from 17 European 
      countries. Choice of therapy was solely at the investigators' discretion. In 
      total, 4173 patients were on conventional HF-treatment (non-S/V group), while 
      4614 patients were on sacubitril/valsartan either at enrolment or started 
      sacubitril/valsartan within 1 month of enrolment (S/V group). Of these, 2108 
      patients started sacubitril/valsartan treatment +/-1 month around enrolment 
      [restricted S/V (rS/V) group]. The average age of the patients was 68 years. 
      Patients on S/V were more likely to have New York Heart Association (NYHA) class 
      III or IV symptoms (50.3%, 44.6%, 32.1% in rS/V, S/V, and non-S/V, respectively) 
      and had lower left ventricular ejection fraction (LVEF; 32.3%, 32.7%, and 35.4% 
      in rS/V, S/V, and non-S/V, respectively; P < 0.0001). The most frequently 
      received HF treatments were angiotensin-converting enzyme inhibitor/angiotensin 
      receptor blocker (ACEI/ARB;  approximately 84% in non-S/V), followed by beta-blockers ( approximately 80%) and 
      mineralocorticoid receptor antagonists (MRAs; 53%). The use of triple HF therapy 
      (ACEI/ARB/angiotensin receptor neprilysin inhibitor with beta-blockers and MRA) was 
      higher in the S/V groups than non-S/V group (48.2%, 48.2%, and 40.2% in rS/V, 
      S/V, and non-S/V, respectively). CONCLUSION: In this large multinational HFrEF 
      registry, patients receiving sacubitril/valsartan tended to be younger with lower 
      LVEF and higher NYHA class. Fewer than half of the patients received triple HF 
      therapy.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. (c) 
      The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.
FAU - Zeymer, Uwe
AU  - Zeymer U
AD  - Klinikum Ludwigshafen, Medizinische Klinik B and Institut fur 
      Herzinfarktforschung, Bremserstrasse 79, 67063 Ludwigshafen-am-Rhein, Germany.
FAU - Clark, Andrew L
AU  - Clark AL
AD  - Castle Hill Hospital, Kingston Upon Hull, Castle Rd, Cottingham HU16 5JQ, United 
      Kingdom.
FAU - Barrios, Vivencio
AU  - Barrios V
AD  - Department of Cardiology, Ramon y Cajal Hospital, Ctra. de Colmenar Viejo km. 
      9,100 28034 Madrid, Spain.
FAU - Damy, Thibaud
AU  - Damy T
AUID- ORCID: 0000-0003-4058-3848
AD  - Department of Cardiology, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000 
      Creteil, France.
FAU - Drozdz, Jaroslaw
AU  - Drozdz J
AD  - Department Cardiology Medical University of Lodz, Poland 92-213 Lodz, Pomorska 
      251, Poland.
FAU - Fonseca, Candida
AU  - Fonseca C
AD  - Hospital de Sao Francisco Xavier, Estrada Forte do Alto do Duque, 1449-005, 
      Lisbon, Portugal.
FAU - Lund, Lars H
AU  - Lund LH
AD  - Department of Medicine, Unit of Cardiology, Karolinska Institutet and Karolinska 
      University HospitalFoU Tema Hjarta Karl, Eugeniavagen 3, Norrbacka, S1:02, 171 76 
      Stockholm, Sweden.
FAU - Kalus, Stefanie
AU  - Kalus S
AD  - GKM Gesellschaft fur Therapieforschung mbH, Lessingstr. 14, 80336 Munich, 
      Germany.
FAU - Ferber, Philippe C
AU  - Ferber PC
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Hussain, Rizwan I
AU  - Hussain RI
AD  - Arxx Therapeutics, Gaustadalleen 21, 0349 Oslo, Norway.
AD  - Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen, Denmark.
FAU - Koch, Cornelia
AU  - Koch C
AD  - Novartis Pharma AG, Basel, Switzerland.
FAU - Maggioni, Aldo P
AU  - Maggioni AP
AUID- ORCID: 0000-0003-2764-6779
AD  - Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Via La 
      Marmora 34, 50121 Florence, Italy.
AD  - Maria Cecilia Hospital, GVM Care & Research, Via Corriera, 1, 48033 Cotignola RA, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J Qual Care Clin Outcomes
JT  - European heart journal. Quality of care & clinical outcomes
JID - 101677796
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Tetrazoles)
RN  - 17ERJ0MKGI (sacubitril)
RN  - 80M03YXJ7I (Valsartan)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aminobutyrates/therapeutic use
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors
MH  - Biphenyl Compounds
MH  - *Heart Failure/drug therapy/epidemiology
MH  - Humans
MH  - Registries
MH  - Stroke Volume
MH  - Tetrazoles/therapeutic use
MH  - Treatment Outcome
MH  - Valsartan
MH  - *Ventricular Dysfunction, Left
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - ARNI
OT  - Guideline adherence
OT  - Heart failure with reduced ejection fraction
OT  - Outpatient
OT  - Real-world evidence
OT  - sacubitril/valsartan
EDAT- 2021/03/17 06:00
MHDA- 2022/06/09 06:00
CRDT- 2021/03/16 17:30
PHST- 2020/12/14 00:00 [received]
PHST- 2021/02/26 00:00 [revised]
PHST- 2021/03/12 00:00 [accepted]
PHST- 2021/03/17 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2021/03/16 17:30 [entrez]
AID - 6174162 [pii]
AID - 10.1093/ehjqcco/qcab019 [doi]
PST - ppublish
SO  - Eur Heart J Qual Care Clin Outcomes. 2022 Jun 6;8(4):469-477. doi: 
      10.1093/ehjqcco/qcab019.